

BRAINSTORM CELL THERAPEUTICS INC.

Form 8-K

June 10, 2014

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 5, 2014

Brainstorm Cell Therapeutics Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

000-54365

(Commission File No.)

20-8133057

(IRS Employer Identification No.)

605 Third Avenue, 34th Floor

New York, NY

10158

(Address of principal executive offices) (Zip Code)

(646) 666-3188

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure

On June 10, 2014 at 8:45 a.m. Eastern Time, Brainstorm Cell Therapeutics Inc. (the “Company”) will hold a conference call pursuant to notice previously given on June 5, 2014 via press release. Callers may participate in the conference call by dialing:

USA: 1-888-407-2553

Canada: 1-866-485-2399

Israel: 03-918-0644

International: +972-3-918-0644

Mr. Chaim Lebovits, the Company's President, and other senior management members are expected to provide an update to stockholders and discuss major Company developments, including:

- Commencement of the Company's Phase II ALS clinical trial announced on June 6, 2014;
- Changes in Company management, including the appointment of Tony Fiorino, MD, PhD as its new Chief Executive Officer as announced on June 9, 2014; and
- Pre-clinical study in autism.

A recording of the conference call will be posted by Wednesday, June 11, 2014 on the Company's website: www.brainstorm-cell.com.

